Beranda › Sarkoma Jaringan Lunak
Uji klinis Sarkoma Jaringan Lunak yang merekrut di AS
137 studi untuk Sarkoma Jaringan Lunak merekrut peserta di lokasi di seluruh Amerika Serikat.
Kota dengan studi terbanyak
- Houston, TX33 studi
- New York City, NY20 studi
- Boston, MA18 studi
- St. Louis, MO14 studi
- Los Angeles, CA13 studi
- Columbus, OH13 studi
- Washington, DC12 studi
- Memphis, TN11 studi
- Philadelphia, PA10 studi
- Nashville, TN9 studi
- Rochester, MN9 studi
- Queens, NY9 studi
- Aurora, CO9 studi
- Atlanta, GA8 studi
- Grand Rapids, MI8 studi
- Durham, NC8 studi
- Baldwin Park, CA7 studi
- Chicago, IL7 studi
- Greenburgh, NY7 studi
- Edison, NJ7 studi
- Santa Monica, CA7 studi
- Orange, CA6 studi
- Baltimore, MD6 studi
- Mountain View, CA6 studi
- Dallas, TX6 studi
- Miami, FL6 studi
- Staten Island, NY6 studi
- East Norwalk, CT6 studi
- New Rochelle, NY6 studi
- Cincinnati, OH5 studi
- Cleveland, OH5 studi
- San Francisco, CA5 studi
- Arlington, VA5 studi
- Pittsburgh, PA5 studi
- Omaha, NE5 studi
- Birmingham, AL5 studi
- Portland, OR4 studi
- Minneapolis, MN4 studi
- San Antonio, TX4 studi
- Jacksonville, FL4 studi
Berdasarkan negara bagian
- Alabama6 studi
- Arizona6 studi
- California41 studi
- Colorado13 studi
- Connecticut5 studi
- Distrik Columbia7 studi
- Florida20 studi
- Georgia10 studi
- Illinois9 studi
- Indiana4 studi
- Iowa4 studi
- Kansas4 studi
- Kentucky3 studi
- Louisiana3 studi
- Maryland11 studi
- Massachusetts19 studi
- Michigan11 studi
- Minnesota13 studi
- Missouri15 studi
- Nebraska5 studi
- New Jersey8 studi
- New Mexico3 studi
- New York28 studi
- North Carolina13 studi
- Ohio23 studi
- Oregon4 studi
- Pennsylvania15 studi
- South Carolina3 studi
- Tennessee19 studi
- Texas38 studi
- Utah6 studi
- Virginia7 studi
- Washington3 studi
- Wisconsin5 studi
Studi yang baru diperbarui
Teks studi resmi (Bahasa Inggris)
A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)
Menerima pesertaFase 1/2
Semua usia · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT07602777Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06528769177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT07189871FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma
Menerima pesertaFase 1
Usia 3 hingga 39 · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT06865664Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT06498648Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies
Menerima pesertaStudi observasionalSukarelawan sehat diterima
4 Weeks · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT01109394A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Menerima pesertaFase 1/2
Hingga usia 25 · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT04094610DESTINY-PANTUMOUR04
Menerima pesertaStudi observasional
Usia 18 hingga 130 · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07124000A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT07229313Anti-GD2 ADC M3554 in Advanced Solid Tumors
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT06641908A Study of CRD3874-SI in People With Solid Tumors
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 21 Sep 2026 · NCT06021626A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Sep 2026 · NCT07705334Biomarkers of Resiliency In Childhood Cancer Surgery
Menerima pesertaStudi observasional
Usia 3 hingga 25 · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT06674811First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Sep 2026 · NCT06797999Minibeam Radiation Therapy With Tungsten Slit Collimator for the Treatment of Recurrent or Metastatic Skin or Soft Tissue Tumors
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Sep 2026 · NCT07062003Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT04577014Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT05732831Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Menerima pesertaFase 1
Usia 12 hingga 85 · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT03715933First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Sep 2026 · NCT06644755Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Sep 2026 · NCT05711615Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas
Menerima pesertaFase 1
Usia 5 hingga 40 · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT06156410GRID Therapy for Extremity Soft Tissue Sarcoma
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT06073067Domatinostat With Sirolimus for Relapsed, Refractory Sarcoma and Osteosarcoma
Menerima pesertaFase 1/2
Usia 12 hingga 40 · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT07725380A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT06760819Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women
Menerima pesertaStudi observasional
Usia 18 hingga 50 · Wanita · Diperbarui 2 Sep 2026 · NCT06904365Dari ClinicalTrials.gov, data diambil 2 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.